Incidence and predictors of hypertension in adults with HIV-initiating antiretroviral therapy in south-western Uganda.
Incidence and predictors of hypertension in adults with HIV-initiating antiretroviral therapy in south-western Uganda.
复制标题
乌干达西南部的HIV发射抗逆转录病毒疗法的成年人的高血压发病率和预测因子。
DOI：
10.1097/hjh.0000000000000657
复制
发表时间：
2015-10
影响因子：
4.9
通讯作者：
Siedner MJ
中科院分区：
文献类型：
--
作者：
Okello S;Kanyesigye M;Muyindike WR;Annex BH;Hunt PW;Haneuse S;Siedner MJ
Objective:The successful scale-up of antiretroviral therapy (ART) in sub-Saharan Africa has led to increasing life expectancy, and thus increased risk of hypertension. We aimed to describe the incidence and predictors of hypertension in HIV patients receiving ART at a publicly funded clinic in rural Uganda.Methods:We abstracted data from medical records of adult patients who initiated ART at an HIV clinic in south-western Uganda during 2010–2012. We defined hypertension as at least two consecutive clinical visits, with a SBP at least 140 mmHg and/or SBP of at least 90 mmHg, or prescription for an antihypertensive medication. We calculated the incidence of hypertension and fit multivariable Cox proportional-hazards models to identify predictors of hypertension.Results:A total of 3389 patients initiated ART without a prior diagnosis of hypertension during the observation period. Over 3990 person-years of follow-up, 445 patients developed hypertension, for a crude incidence of 111.5/1000 (95% confidence interval 101.9–121.7) person-years. Rates were highest among men aged at least 40 years (158.8 per/1000 person-years) and lowest in women aged 30–39 years (80/1000 person-years). Lower CD4+ cell count at ART initiation, as well as traditional risk factors including male sex, increasing age, and obesity, were independently associated with hypertension.Conclusion:We observed a high incidence of hypertension in HIV-infected persons on ART in rural Uganda, and increased risk with lower nadir CD4+ cell counts. Our findings call for increased attention to screening of and treatment for hypertension, along with continued prioritization of early ART initiation.
